查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813426

2032 年醫藥化學品市場預測：按化學類型、治療領域、最終用戶和地區進行的全球分析

Pharmaceutical Chemicals Market Forecasts to 2032 - Global Analysis By Chemical Type (Active Pharmaceutical Ingredients (APIs), Excipients, Intermediates, Solvents and Reagents), Therapeutic Area, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球醫藥化學品市場預計在 2025 年達到 1,353.2 億美元，到 2032 年將達到 2,274.5 億美元，預測期內複合年成長率為 7.7%。

醫藥化學品是當今醫療治療的重要基礎。它們由活性藥物成分 (API)、中間體和輔料組成，每種成分在藥物生產中發揮不同的作用。 API 發揮主要的治療作用，而中間體則在 API 的合成過程中充當過渡化合物。輔料透過改善非活性成分、穩定性、口感、吸收和持續時間來增強藥效。透過為片劑、糖漿、膠囊和注射劑提供可靠的原料，我們的醫藥化學物品部門確保了藥品的品質和功效。最終，這些化學物質對全球醫療保健至關重要，支持疾病管理、康復和改善健康。

根據國際製藥商協會聯合會 (IFPMA) 的數據，目前全球有超過 9,000 種化學化合物正在開發中，這一數字凸顯了藥物研發的規模之大，其中化學合成和配方在推動治療方法創新方面發揮著重要作用。

學名藥需求不斷成長

對學名藥日益成長的依賴是醫藥化學品行業的主要驅動力。隨著專利到期，製造商面臨開發價格合理且與原廠藥具有相同療效的替代藥物的壓力。這導致對原料藥、中間體和輔料的需求增加，以確保藥物製劑的品質和可靠性。各國政府和醫療保健組織正積極鼓勵採用學名藥，以降低醫療成本並提高病患的便利性。因此，醫藥化學品的生產正在迅速擴張。生產商需要提供可靠的高品質原料，而學名藥浪潮是刺激該市場成長的關鍵因素。

製造和研發成本高

高昂的製造和研發成本是醫藥化學品產業的一大障礙。創造新的原料藥、中間體和輔料需要最先進的基礎設施、專業知識和昂貴的原料。監管申報、臨床試驗和安全研究進一步加重了這個過程的負擔，所有這些都增加了支出。日益激烈的學名藥競爭往往會降低盈利，阻礙許多公司在創新方面進行大規模投資。中小企業面臨的風險最大，因為它們缺乏長期研究所需的財務穩定性。因此，新化合物的引入仍然有限，減緩了市場擴張，並增加了對大型資源豐富的公司的依賴。

在新興市場擴張

新興經濟體為醫藥化學品市場成長提供了巨大的機會。亞太、非洲和拉丁美洲各國收入不斷成長，醫療設施不斷擴大，人口不斷成長，推動了藥品需求的不斷成長。價格實惠的學名藥在這些地區佔據主導地位，對原料藥、中間體和輔料的需求強勁。許多政府優先發展本地生產以減少進口，這為醫藥化學品供應商提供了在該地區立足的機會。與國內製藥公司的合作進一步鼓勵了跨國公司進入這些快速成長的地區。隨著醫療保健支出和醫療可近性的不斷提高，新興市場為醫藥化學品行業的長期擴張提供了巨大的潛力。

市場競爭激烈

激烈的競爭對醫藥化學品產業構成了重大威脅。眾多區域和國際公司爭奪原料藥、中間體和輔料的供應，迫使各公司在保持高品質的同時降低價格。學名藥製造商的崛起進一步加劇了競爭，因為醫療保健系統更青睞價格更低的替代品。這種情況降低了利潤率，並減少了用於研發和創新的資金。中小企業面臨的風險最大，因為它們缺乏跨國公司的規模和資源。隨著市佔率爭奪戰的加劇，保持盈利和獨特性變得更加困難，這對尋求保持競爭力的醫藥化學品製造商來說是一個長期挑戰。

COVID-19的影響：

新冠疫情危機對醫藥化學品產業造成了重大影響。供應鏈中斷導致原料藥、中間體和其他原料的運輸延誤，擾亂了許多製藥商的生產。同時，疫苗、抗病毒藥物和支持性治療的需求激增，為化學品供應商創造了巨大的商機。企業必須迅速調整產能，實施嚴格的安全措施，並滿足不斷變化的監管要求。疫情在帶來營運和物流障礙的同時，也刺激了技術創新，增加了對醫藥研發的投資，並凸顯了醫藥化學品在醫療保健體系中的關鍵作用。這段時期既凸顯了該產業在全球衛生緊急事件中的脆弱性，也凸顯了其戰略重要性。

循環系統領域預計將成為預測期內最大的領域

預計循環系統領域將在預測期內佔據最大的市場佔有率。在全球範圍內，高血壓、心肌梗塞和中風等心血管疾病的發生率不斷上升，推動了相關藥物的持續需求。藥物研發的進步，例如聯合治療和耐受性更高的製劑，進一步推動了這項需求。此外，隨著全球人口老化，對心血管治療的需求也不斷成長。這一趨勢推動了對心血管特異性活性化合物和中間體合成的持續投資。因此，心血管治療領域將繼續成為醫藥化學品行業收入的最大貢獻者。

預計預測期內受託製造廠商(CMO) 部門的複合年成長率最高。

預計受託製造廠商(CMO) 細分市場將在預測期內實現最高成長率。這種快速成長源於製藥公司擴大將其製造業務外包給 CMO，以降低成本、提高生產效率並專注於研發和行銷。此外，CMO 還提供活性藥物成分 (API) 合成、配方開發、品質保證和包裝等專業服務，由於對經濟實惠、可擴展且可靠的製藥製造解決方案的需求不斷成長，這些服務的需求也日益旺盛。

佔比最大的地區：

預計北美將在預測期內佔據最大的市場佔有率。這一領先地位得益於其集中的知名製藥公司、先進的研發設施和完善的醫療保健體系。美國憑藉其眾多經營大型生產工廠和研發中心的大型主要企業而脫穎而出。此外，有利的專利法和智慧財產權保護也正在推動該地區的創新。北美專注於開發新型療法和生物標記物，並嚴格遵守美國食品藥物管理局 (FDA) 等機構強制執行的品質標準，鞏固了其在醫藥化學品領域的主導地位。

複合年成長率最高的地區：

預計亞太地區在預測期內將實現最高的複合年成長率。主要促進因素包括醫療保健支出的增加、製藥產能的擴張以及新興經濟體對活性藥物成分 (API) 日益成長的需求。中國和印度等國家正在推動這一成長，這得益於其在研發方面的大量投資以及強勁的製藥業。此外，該地區人口眾多且老化，加上慢性病的發病率上升，這些因素都刺激了對醫藥化學品的需求。因此，預計亞太地區未來幾年將出現顯著的市場成長。

免費客製化服務

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球醫藥化學品市場（依化學類型）

  • 活性藥物成分（API）
    • 合成 API
    • 生物技術 API
  • 輔料
  • 中間體
  • 溶劑
  • 試劑

6. 全球醫藥化學品市場（依治療領域）

  • 腫瘤學
  • 心血管系統
  • 中樞神經系統（CNS）
  • 感染疾病
  • 內分泌學
  • 呼吸系統
  • 皮膚科
  • 胃腸病學
  • 其他治療領域

7. 全球醫藥化學品市場（依最終用戶分類）

  • 製藥商
  • 契約製造組織（CMO）
  • 藥物研究與開發研究所
  • 化學品供應商和經銷商

8. 全球醫藥化學品市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第9章：主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章：企業概況

  • Sun Pharma
  • Dr. Reddy's Labs
  • Aurobindo Pharma
  • Cipla
  • Zydus Life
  • Lupin
  • Biocon
  • Glenmark Pharma
  • Alkem Lab
  • Torrent Pharma
  • Divis Labs
  • Piramal Pharma
  • Ipca Labs
  • Aarti Industries
  • Kajay Remedies
Product Code: SMRC30875

According to Stratistics MRC, the Global Pharmaceutical Chemicals Market is accounted for $135.32 billion in 2025 and is expected to reach $227.45 billion by 2032 growing at a CAGR of 7.7% during the forecast period. Pharmaceutical chemicals form the essential foundation of today's medical treatments. They consist of active pharmaceutical ingredients (APIs), intermediates, and excipients, each serving distinct functions in drug creation. APIs deliver the primary therapeutic action, while intermediates act as transitional compounds in the synthesis of these APIs. Excipients, although not medicinally active, enhance drug performance by improving stability, taste, absorption, and durability. By providing reliable raw materials for tablets, syrups, capsules, and injectable solutions, the pharmaceutical chemical sector ensures the quality and effectiveness of medications. Ultimately, these chemicals are indispensable to global healthcare, supporting disease management, recovery, and the improvement of human health.

According to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), there are currently over 9,000 compounds at different stages of development globally. This figure highlights the immense scale of pharmaceutical R&D, where chemical synthesis and formulation play a foundational role in advancing therapeutic innovation.

Market Dynamics:

Driver:

Rising demand for generic drugs

Growing reliance on generic medicines is strongly fueling the pharmaceutical chemicals industry. With patent expirations of leading drugs, manufacturers are compelled to develop affordable alternatives that maintain the same therapeutic effectiveness as branded options. To achieve this, there is heightened demand for APIs, intermediates, and excipients that ensure quality and reliability in drug formulations. Governments and healthcare organizations actively encourage generic adoption to lower medical expenses and enhance accessibility for patients. Consequently, the production of pharmaceutical chemicals is expanding rapidly. Producers must deliver reliable, high-standard raw materials, making the generic drug wave a pivotal factor stimulating growth in this market.

Restraint:

High production and R&D costs

High manufacturing and R&D expenses pose a considerable barrier in the pharmaceutical chemicals industry. Creating new APIs, intermediates, or excipients demands cutting-edge infrastructure, specialized knowledge, and costly raw materials. The process is further burdened by regulatory filings, clinical testing, and safety trials, all of which escalate spending. Profitability often suffers as rising generic competition reduces returns, leaving many companies hesitant to invest heavily in innovation. Small and medium enterprises face the greatest risk since they lack financial stability for long-term research. Consequently, the introduction of novel chemical entities remains limited, slowing market expansion and reinforcing reliance on larger corporations with robust resources.

Opportunity:

Expansion in emerging markets

Developing economies present vast opportunities for growth in the pharmaceutical chemicals market. Nations across Asia-Pacific, Africa, and Latin America are experiencing rising incomes, expanding healthcare facilities, and larger populations, fueling higher demand for medicines. Affordable generics dominate these regions, creating strong requirements for APIs, intermediates, and excipients. Many governments are prioritizing local manufacturing to minimize imports, giving suppliers of pharmaceutical chemicals a chance to establish themselves regionally. Partnerships with domestic pharmaceutical firms further support global companies in entering these fast-growing areas. As healthcare spending and accessibility rise, emerging markets offer significant potential for long-term expansion in the pharmaceutical chemicals industry.

Threat:

Intense market competition

Fierce rivalry significantly threatens the pharmaceutical chemicals sector. Numerous regional and international firms compete by supplying APIs, intermediates, and excipients, forcing companies to cut prices while ensuring high quality. The rise of generic drug manufacturers makes the competition even tougher, as healthcare systems favor cheaper alternatives. Such conditions erode profit margins, leaving fewer funds for research and innovation. Smaller companies face the greatest risk since they lack the scale and resources of global corporations. As the battle for market share grows, maintaining profitability and distinctiveness becomes more difficult, creating long-term challenges for pharmaceutical chemical producers trying to remain competitive.

Covid-19 Impact:

The COVID-19 crisis significantly influenced the pharmaceutical chemicals industry. Supply chain interruptions delayed shipments of APIs, intermediates, and other raw materials, disrupting production for numerous pharmaceutical manufacturers. Simultaneously, the sudden surge in demand for vaccines, antiviral medications, and supportive treatments generated substantial opportunities for chemical suppliers. Firms needed to rapidly adjust production capacities, implement strict safety measures, and meet evolving regulatory requirements. Although the pandemic introduced operational and logistical obstacles, it also spurred innovation, increased investments in pharmaceutical research and development, and emphasized the essential role of pharmaceutical chemicals in healthcare systems. This period demonstrated both the vulnerabilities and strategic importance of the industry during global health emergencies.

The cardiovascular segment is expected to be the largest during the forecast period

The cardiovascular segment is expected to account for the largest market share during the forecast period. The global rise in cardiovascular disorders-such as hypertension, myocardial infarction, and stroke-drives sustained demand for related medications. Advances in drug development, including combination therapies and formulations with enhanced tolerability, further boost this demand. Moreover, as populations age worldwide, the necessity for cardiovascular treatments grows stronger. These dynamics continuously funnel investment into the synthesis of cardiovascular-specific active compounds and intermediates. As a result, the cardiovascular therapeutic area remains the foremost contributor by revenue in the pharmaceutical chemicals sector.

The contract manufacturing organizations (CMOs) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the contract manufacturing organizations (CMOs) segment is predicted to witness the highest growth rate. This rapid growth stems from the increasing tendency of pharmaceutical companies to outsource manufacturing operations to CMOs to lower costs, enhance production efficiency, and focus on research, development, and marketing. Additionally, CMOs provide expert services including active pharmaceutical ingredient (API) synthesis, formulation development, quality assurance, and packaging, which are highly sought after due to the growing demand for affordable, scalable, and reliable drug manufacturing solutions.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. This leadership is driven by the concentration of prominent pharmaceutical firms, cutting-edge research and development facilities, and a well-established healthcare system. The United States stands out with its numerous leading pharmaceutical companies operating large-scale production plants and R&D hubs. Furthermore, favorable patent laws and intellectual property protections encourage innovation within the region. North America's emphasis on creating novel therapeutics and biomarkers, along with adherence to rigorous quality standards enforced by agencies such as the U.S. FDA, solidifies its dominant role in the pharmaceutical chemicals sector.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. Key drivers include increased healthcare expenditure, the expansion of pharmaceutical manufacturing capacities, and a heightened need for active pharmaceutical ingredients (APIs) in developing economies. Nations such as China and India are leading this growth, bolstered by substantial investments in research and development and the presence of a robust pharmaceutical industry. Furthermore, the region's large and aging population, coupled with a rising incidence of chronic diseases, is fueling the demand for pharmaceutical chemicals. Consequently, the APAC region is poised for significant market growth in the coming years.

Key players in the market

Some of the key players in Pharmaceutical Chemicals Market include Sun Pharma, Dr. Reddy's Labs, Aurobindo Pharma, Cipla, Zydus Life, Lupin, Biocon, Glenmark Pharma, Alkem Lab, Torrent Pharma, Divis Labs, Piramal Pharma, Ipca Labs, Aarti Industries and Kajay Remedies.

Key Developments:

In July 2025, Sun Pharmaceutical Industries Ltd has announced that it has entered into a settlement and license agreement with Incyte Corporation regarding litigation related to LEQSELVI. Under the terms of agreement, the parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation.

In February 2025, Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a daratumumab biosimilar candidate to Johnson & Johnson's (J&J) Darzalex & Darzalex Faspro. Darzalex & Darzalex Faspro are indicated to treat multiple myeloma. The partnership leverages Dr. Reddy's worldwide commercial network along with Henlius' expertise in biosimilar development.

In November 2024, Aurobindo Pharma's US faction has entered into collaboration and licensing agreement with a global pharmaceutical company. The agreement will focus on the development of respiratory therapeutics, with associated costs being shared equally between the partners. The development period is predicted to span around three to five years, with Aurobindo's total spend in this portion of the deal capped at USD $90m.

Chemical Types Covered:

  • Active Pharmaceutical Ingredients (APIs)
  • Excipients
  • Intermediates
  • Solvents
  • Reagents

Therapeutic Areas Covered:

  • Oncology
  • Cardiovascular
  • Central Nervous System (CNS)
  • Infectious Diseases
  • Endocrinology
  • Respiratory
  • Dermatology
  • Gastroenterology
  • Other Therapeutic Areas

End Users Covered:

  • Pharmaceutical Manufacturers
  • Contract Manufacturing Organizations (CMOs)
  • Pharmaceutical R&D Institutions
  • Chemical Suppliers & Distributors

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Pharmaceutical Chemicals Market, By Chemical Type

  • 5.1 Introduction
  • 5.2 Active Pharmaceutical Ingredients (APIs)
    • 5.2.1 Synthetic APIs
    • 5.2.2 Biotech APIs
  • 5.3 Excipients
  • 5.4 Intermediates
  • 5.5 Solvents
  • 5.6 Reagents

6 Global Pharmaceutical Chemicals Market, By Therapeutic Area

  • 6.1 Introduction
  • 6.2 Oncology
  • 6.3 Cardiovascular
  • 6.4 Central Nervous System (CNS)
  • 6.5 Infectious Diseases
  • 6.6 Endocrinology
  • 6.7 Respiratory
  • 6.8 Dermatology
  • 6.9 Gastroenterology
  • 6.10 Other Therapeutic Areas

7 Global Pharmaceutical Chemicals Market, By End User

  • 7.1 Introduction
  • 7.2 Pharmaceutical Manufacturers
  • 7.3 Contract Manufacturing Organizations (CMOs)
  • 7.4 Pharmaceutical R&D Institutions
  • 7.5 Chemical Suppliers & Distributors

8 Global Pharmaceutical Chemicals Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Sun Pharma
  • 10.2 Dr. Reddy's Labs
  • 10.3 Aurobindo Pharma
  • 10.4 Cipla
  • 10.5 Zydus Life
  • 10.6 Lupin
  • 10.7 Biocon
  • 10.8 Glenmark Pharma
  • 10.9 Alkem Lab
  • 10.10 Torrent Pharma
  • 10.11 Divis Labs
  • 10.12 Piramal Pharma
  • 10.13 Ipca Labs
  • 10.14 Aarti Industries
  • 10.15 Kajay Remedies

List of Tables

  • Table 1 Global Pharmaceutical Chemicals Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Pharmaceutical Chemicals Market Outlook, By Chemical Type (2024-2032) ($MN)
  • Table 3 Global Pharmaceutical Chemicals Market Outlook, By Active Pharmaceutical Ingredients (APIs) (2024-2032) ($MN)
  • Table 4 Global Pharmaceutical Chemicals Market Outlook, By Synthetic APIs (2024-2032) ($MN)
  • Table 5 Global Pharmaceutical Chemicals Market Outlook, By Biotech APIs (2024-2032) ($MN)
  • Table 6 Global Pharmaceutical Chemicals Market Outlook, By Excipients (2024-2032) ($MN)
  • Table 7 Global Pharmaceutical Chemicals Market Outlook, By Intermediates (2024-2032) ($MN)
  • Table 8 Global Pharmaceutical Chemicals Market Outlook, By Solvents (2024-2032) ($MN)
  • Table 9 Global Pharmaceutical Chemicals Market Outlook, By Reagents (2024-2032) ($MN)
  • Table 10 Global Pharmaceutical Chemicals Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 11 Global Pharmaceutical Chemicals Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 12 Global Pharmaceutical Chemicals Market Outlook, By Cardiovascular (2024-2032) ($MN)
  • Table 13 Global Pharmaceutical Chemicals Market Outlook, By Central Nervous System (CNS) (2024-2032) ($MN)
  • Table 14 Global Pharmaceutical Chemicals Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 15 Global Pharmaceutical Chemicals Market Outlook, By Endocrinology (2024-2032) ($MN)
  • Table 16 Global Pharmaceutical Chemicals Market Outlook, By Respiratory (2024-2032) ($MN)
  • Table 17 Global Pharmaceutical Chemicals Market Outlook, By Dermatology (2024-2032) ($MN)
  • Table 18 Global Pharmaceutical Chemicals Market Outlook, By Gastroenterology (2024-2032) ($MN)
  • Table 19 Global Pharmaceutical Chemicals Market Outlook, By Other Therapeutic Areas (2024-2032) ($MN)
  • Table 20 Global Pharmaceutical Chemicals Market Outlook, By End User (2024-2032) ($MN)
  • Table 21 Global Pharmaceutical Chemicals Market Outlook, By Pharmaceutical Manufacturers (2024-2032) ($MN)
  • Table 22 Global Pharmaceutical Chemicals Market Outlook, By Contract Manufacturing Organizations (CMOs) (2024-2032) ($MN)
  • Table 23 Global Pharmaceutical Chemicals Market Outlook, By Pharmaceutical R&D Institutions (2024-2032) ($MN)
  • Table 24 Global Pharmaceutical Chemicals Market Outlook, By Chemical Suppliers & Distributors (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.